Comparison of Glimepiride and Gliclazide in type-2 diabetes

Adding Glimepiride or Gliclazide to Metformin improves glycemic control and lipid levels, reducing hypoglycemia in type 2 diabetics.

This study investigated Glimepiride and Gliclazide efficacy with Metformin for T2DM despite Metformin's first-line preference.

60 T2DM patients were randomized into two groups: Group A received Glimepiride 2 mg + Metformin 1500 mg and Group B received Gliclazide 80 mg + Metformin 1500 mg. Parameters including HbA1c, lipid profile, BMI, and blood counts were assessed at baseline and after 12 weeks. Fasting and postprandial blood glucose levels were measured at 4, 8 and 12 weeks. Adverse events were monitored throughout.

Both groups A and B showed meaningful reductions in HbA1c, fasting blood sugar, and post-prandial blood sugar (PPBS), with no statistically significant difference between them.

Lipid levels decreased remarkably in both groups except for high-density lipoprotein and low-density lipoprotein in the Gliclazide group. Adverse events like nausea, diarrhoea, and epigastric pain were reported similarly in both groups.

Glimepiride and Gliclazide are equally effective in improving glycemic control when added to Metformin in T2DM management.